Predicted Trait | |
Reported Trait | Triple negative breast cancer |
Mapped Trait(s) | triple-negative breast cancer (EFO_0005537) |
Score Construction | |
PGS Name | TNBC_PRS41 |
Development Method | |
Name | Suggestive genome-wide significant SNPs |
Parameters | After removal of variants with MAF < 0.01, an imputation quality score r2 of < 0.8, small INDELs, and the C/G or A/T SNPs due to strand ambiguity, SNPs with P<5×10-7 were included. The SNPs were then clumped using r2<0.1, and the 1000 Genomes Phase 3 EUR data as the LD reference. |
Variants | |
Original Genome Build | GRCh37 |
Number of Variants | 41 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000620 |
Citation (link to publication) | Sun X et al. Cancer Res (2024) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 100,079 individuals (100%) |
PGS Evaluation |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
Europe PMC: 32424353 |
[
|
European | BCAC |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM021272 | PSS011672| Multi-ancestry (including European)| 9,868 individuals |
PGP000620 | Sun X et al. Cancer Res (2024) |
Reported Trait: Triple negative breast cancer | — | — | Odds ratio (OR, high vs low tertile): 1.53 [0.92, 2.55] | Age at initial pathologic diagnosis of breast cancer, pathologic stage | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011672 | The molecular intrinsic subtypes of breast cancer were determined following the strategy of Giovanni's work using the PAM50 classifier in the TCGA-BRCA. Basal-like and luminal-like breast cancer were determined by PAM50. | — | [
|
— | European | — | TCGA | — |
PSS011672 | Triple-negative breast cancer (TNBC) was defined as ER negative, PR negative and HER2 negative. The luminal breast cancer was defined as ER and/or PR positive. | — | [
|
— | African American or Afro-Caribbean | — | AABCG | — |